RNAi therapeutics firm Alnylam Pharmaceuticals and consumer genetics firm 23andMe will offer free genetic test kits to first-degree family members of 23andMe customers who have a TTR variant known to cause hereditary amyloidosis.

Illumina will bring its genomics startup incubator to the UK next year.

The Parkinson's Foundation and Fulgent Genetics announced recently that they have begun a collaboration on a new genetic testing initiative for Parkinson's disease patients.

Abbott recently said that its Diagnostics business revenues grew 2 percent year over year in the second quarter, while its total revenues were up 3 percent.

PathogenDx has entered into a strategic partnership with Nationwide Laboratory Services for fungal testing of dermatology and podiatry samples.

Danaher recently reported a 4 percent year-over-year increase in its second quarter revenues, which included a 6 percent rise in life sciences segment revenues and a rise of almost 5 percent in its diagnostics segment.

Life sciences and health data startup Seer announced recently that it has raised $17.5 million in a series C financing round.

Danaher recently announced that the group will establish an independent company, ENVISTA HOLDINGS CORPORATION (referred to as Envista), and will make an initial public offering in the second half of 2019.

Quanterix announced after the close of the market on Wednesday that it has inked an agreement to acquire privately held UmanDiagnostics for $22.5 million.

Illumina has filed patent infringement suits in the US, Switzerland, and Turkey relating to BGI's sequencing instrumentation and chemistry, the company said today.

The global point of care (POC) diagnostics/testing market size is expected to grow at a CAGR of 3.3% over the forecast period 2019-2025 to reach USD 22.8 billion by 2025...

Thermo Fisher Scientific said today that it has acquired HighChem, a developer of mass spectrometry software based in Slovakia.

The global blood gas analyzers market was valued at USD 594.6 million in 2017 and is projected to grow at a CAGR of 5.5% over the forecast period (2018 – 2026) to surpass USD 940 million by 2026.

The global blood coagulation analyzer market is projected to grow at a substantial CAGR of 5.9% over the period 2018 to 2023, driven by its increasing scope, product types, and applications.

Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its liquid biopsy-based ExoDx Prostate IntelliScore (EPI) test in the state.